Brigham & Women’s Hospital, Inc. v. Perrigo Co.

by Robins Kaplan LLP

Robins Kaplan LLP

November 17, 2017

Case Name: Brigham & Women’s Hospital, Inc. v. Perrigo Co., Civ. No. 13-11640-RWZ, 2017 U.S. Dist. LEXIS 190604 (D. Mass. Nov. 17, 2017) (Zobel, S.J.) 

Drug Product and Patent(s)-in-Suit: Pepcid Complete® (amotidine-antacid combination tablet); U.S. Patent No. 5,229,137 (“the ’137 patent”)

Nature of the Case and Issue(s) Presented:  The court held an eight-day jury trial that concluded on Dec. 14, 2016, with a jury verdict in favor of plaintiffs. The jury found: (i) direct, induced, contributory, and willful infringement by Perrigo of all asserted claims of ’137 patent; (ii) an effective priority date of March 1990; and (iii) all asserted claims valid. The jury awarded Brigham $10,210,071 in damages and rejected Perrigo’s laches defense, finding that Brigham knew or should have known of its infringement claim against Perrigo as of August 11, 2008. On Jan. 24, 2017, Perrigo filed several motions for judgment as a matter of law or a new trial under Fed. R. Civ. P. 50(d) and 59(d). Brigham opposed these motions on the ground that they had not been timely filed, and further argued that Perrigo failed to timely appeal. On Apr. 24, 2017, the court denied Perrigo’s post-trial motions. The Federal Circuit, however, ruled that the district court’s Dec. 2016 judgment was not final because “the issue of enhanced damages had not been resolved,” and therefore denied Brigham’s motion to dismiss the appeals. Subsequently, the court entered a final judgment in accordance with the Dec. 2016 jury verdict. The Federal Circuit deactivated the appeals and instructed the court to consider the pending post-judgment motions.

Perrigo sought judgment as a matter of law on standing, infringement, invalidity, and damages, or in the alternative, moved for a new trial on these issues. Perrigo’s Renewed Motion for Judgment as a Matter of Law of No Direct, No Indirect, and No Willful Infringement and Motion for a New Trial was allowed. Perrigo’s Renewed Motions for (i) Judgment of Invalidity as a Matter of Law or New Trial and Motion for Judgment of Invalidity over the Prior Art; and (ii) Judgment as a Matter of Law on Lack of Standing were denied. Brigham’s Motion to Alter Judgment to Award Prejudgment Interest and Perrigo’s Renewed Motion for Judgment as a Matter of Law on Damages, and Motion for Remittitur or New Trial were denied as moot.

Why Perrigo Prevailed: In 1996, Brigham and Johnson & Johnson Merck Consumer Pharmaceuticals (“JJMCP”) entered into an exclusive license agreement that gave JJMCP the first right, but not obligation, “to prosecute ... any infringement of the [’137 patent] that involves products or methods in which FAMOTIDINE is combined or used in combination simultaneously or substantially simultaneously with an ANTACID.” The parties agreed to notify each other promptly of each such infringement of which [Brigham] or JJMCP was or became aware.

Regarding the issue of standing, Perrigo contended that the launch of its generic product in 2008 constituted a separate potentially infringing action apart from the filing of its ANDA in 2005 that triggered the notice requirement under the license agreement. It argued that because Brigham failed to notify JJMCP about Perrigo’s launch of its generic product prior to filing suit in 2013, and thereby failed to trigger the 120-day notice period to seek the requisite authority from JJMCP, Brigham lacked prudential standing to bring suit against Perrigo. Brigham responded that it had standing to sue because: (i) it owned title to the ’137 patent at all times; (ii) the license agreement authorized JJMCP to bring suit only during the effective period of its license; and (iii) JJMCP’s waiver of its right to pursue Perrigo in 2005 “was for any infringement arising of out Perrigo’s activities broadly relating to the ’137 patent occurring prior to patent expiration.” The crux of standing case law had always been the issue of whether a plaintiff had all substantial rights in the patent-at-issue; here, Brigham retained substantial rights in the ’137 patent under the license agreement. Therefore, prudence did not warrant a determination that Brigham lacked standing to sue in this case.

Turning to the issue of infringement, the court found that Brigham failed to present sufficient evidence to prove direct infringement. Brigham’s expert conceded that there was no direct evidence that showed a person who took Perrigo’s product met the limitations of claim 1, namely, the immediate-and-sustained-relief limitation. Instead, Brigham relied on indirect evidence, including bioequivalence data from Perrigo’s ANDA and studies from the NDA for Pepcid Complete that Brigham contended was incorporated into Perrigo’s label. However, the court found that the NDA in Study 098 did not prove that participants were provided immediate relief “from pain, discomfort and/or symptoms associated with episodic heartburn” as required by claim 1 of the ’137 patent. Because Brigham could not prove that its product, Pepcid Complete, read on all the claim limitations of the ’137 patent, it could not, as a matter of law, establish that Perrigo’s generic product infringed.

The court further held that Perrigo was not entitled to judgment as a matter of law on invalidity because it had failed to show by clear and convincing evidence that the “Davis” prior-art reference anticipated the ’137 patent. Davis disclosed the “[c]o-administration of a histamine H2-receptor antagonist and antacid for the treatment of gastric disorders.” Perrigo, however, did not point to any evidence from its affirmative case to support its burden of showing that Davis disclosed the limitation of “immediate and sustained relief” as defined in patent-in-suit.

With regard to obviousness, the parties agreed that a person of ordinary skill in the art at the time of the filing of the application that led to the '137 patent “would include someone with a graduate degree in pharmacy, pharmaceutics, biopharmaceutics or a doctorate in medicine or osteopathic medicine, and at least two years academic, industry, or clinical experience in such fields.” Similar to the shortcoming of Davis, none of the other prior-art references disclosed the key limitation found in claim 1, namely, the “immediate and sustained relief” limitation. Accordingly, the jury’s verdict of non-obviousness for claim 1 and thereby all dependent claims 4, 5, 6, 7, and 12 was supported by substantial evidence.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Robins Kaplan LLP | Attorney Advertising

Written by:

Robins Kaplan LLP

Robins Kaplan LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.


JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at:

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.